NCT05607615View on ClinicalTrials.gov

A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease

PHASE2UnknownINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 23, 2022

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2024

Conditions
Alzheimer's Disease
Interventions
DRUG

Hydroxypropyl Beta Cyclodextrin

Minimum active dose of 500 mg/kg (equivalent to 18,500 mg/m2) as an intravenous (IV) infusion once every 28 days

DRUG

Placebo

0.5N saline as an intravenous (IV) infusion once every 28 days

Trial Locations (5)

32792

RECRUITING

Charter Research, Winter Park

34613

RECRUITING

Access Research Institute, Brooksville

70072

RECRUITING

Tandem/Clincloud, LCC, Marrero

84107

RECRUITING

Wasatch Clinical Research, Salt Lake City

07753

RECRUITING

Advanced Clinical Institute Inc, Neptune City

Sponsors
All Listed Sponsors
lead

Cyclo Therapeutics, Inc.

INDUSTRY

NCT05607615 - A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease | Biotech Hunter | Biotech Hunter